Ok, so Acadia is a one trick pony with Nuplazid and as the elderly patient base passes, new patients are slow to fill the lacking patient base. Nuplazid is not something that young patients stay on for their entire lives for a full profit. Also, Nuplzid can be prescribed off label, so new indication may not increase profits by much. Also, all indication are that the FDA will reject Nuplazid for ADP, do to the Biogen fiasco...Also the med for Rett syndrome has not been approved and it has a small patient base anyway. There are already several meds for schizophrenia treatment. I think the only way to boost profits is to cut the BOD pay on half and for Acadia to seek EU approval for Nuplazid. All indicators appear to show that Acadia is headed into the single digits. Also, the open and un buttoned shirt, style of management by Steve Davis is lackluster at best, especially when he couldn't even answer how is going to deal with the advisory panels objections and recommendation to for a 2nd time, to reject Nuplazid for ADP. We're through the looking glass here folks, all indication are that we are headed for bankruptcy, let's face it, Acadia is 3rd on the Baker Brothers list of holdings, meaning it's the ugly, red-headed step child, which gets no positive attention. Also, Acadia can't pay for another round of ADP trials, without a severe dilution if shares, or worse yet, a reverse split! Now combine that with high inflation, higher interest rates, high gas prices and the increased government take over of health care and big pharma, price controls to lower profits! Also, the BOD members selling off shares of their stock!